ArticleRenal failure2026
Association between triglyceride-glucose index and treatment response in primary membranous nephropathy: a retrospective cohort study.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThe triglyceride-glucose (TyG) index, a marker of insulin resistance, has been linked to chronic kidney disease and proteinuria severity, but its prognostic value for treatment response in primary membranous nephropathy (PMN) is unclear. We evaluated whether baseline TyG predicts 12-month proteinuria remission in PMN.
methodsWe included 363 patients with PMN. The primary outcome was 12-month remission per 2021 KDIGO criteria. Missing covariates were handled by multiple imputation (20 datasets). Multivariable logistic regression adjusted for anti-PLA2R antibody (continuous, per 100 RU/mL), albumin, 24-hour urine protein, age, sex, comorbidities, and treatment group. Sensitivity analyses included TyG tertiles, restriction to standard immunotherapy, complete remission, binary anti-PLA2R status, eGFR adjustment, log-transformed and restricted cubic spline modeling of anti-PLA2R antibody, complete-case analysis, inverse probability of treatment weighting, post-hoc power analysis, and adjustment for treatment switching.
resultsAmong 363 patients, 267 (73.6%) achieved remission. Baseline TyG was not independently associated with remission (OR = 0.839, 95% CI: 0.544-1.293,
conclusionsBaseline TyG was not independently associated with 12-month remission in PMN and provided minimal incremental predictive value. However, a moderate association cannot be excluded given the confidence interval. Anti-PLA2R antibody level showed an inverse association when modeled continuously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.